Hansa Biopharma AB (publ) (LON:0RC7)
London
· Delayed Price · Currency is GBP · Price in SEK 22.72
-0.92 (-3.89%)
At close: Feb 21, 2025
Hansa Biopharma AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 171.32 | 134.09 | 154.53 | 33.88 | 6.1 | Upgrade
|
| Revenue Growth (YoY) | 27.76% | -13.22% | 356.12% | 455.56% | 81.27% | Upgrade
|
| Cost of Revenue | 83.55 | 63.14 | 38.48 | 15.43 | 1 | Upgrade
|
| Gross Profit | 87.76 | 70.95 | 116.05 | 18.45 | 5.1 | Upgrade
|
| Selling, General & Admin | 343.77 | 450.49 | 337.86 | 327.27 | 202.99 | Upgrade
|
| Research & Development | 375.71 | 411.33 | 346.24 | 230.76 | 227.19 | Upgrade
|
| Other Operating Expenses | 5.65 | -2.38 | 8.06 | - | - | Upgrade
|
| Operating Expenses | 725.14 | 859.45 | 692.17 | 558.03 | 430.18 | Upgrade
|
| Operating Income | -637.37 | -788.5 | -576.12 | -539.58 | -425.08 | Upgrade
|
| Interest Expense | -187.17 | -105.52 | -43.67 | -0.69 | -0.26 | Upgrade
|
| Interest & Investment Income | 20.83 | 28.06 | 8.83 | 0.07 | 0.39 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 35.14 | 5.95 | -7.4 | 2.27 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | -4.97 | -0.53 | 1.78 | Upgrade
|
| EBT Excluding Unusual Items | -803.71 | -830.81 | -609.98 | -548.13 | -420.89 | Upgrade
|
| Pretax Income | -803.71 | -830.81 | -609.98 | -548.13 | -420.89 | Upgrade
|
| Income Tax Expense | 3.03 | 0.91 | 1.16 | 0.15 | -0.04 | Upgrade
|
| Net Income | -806.74 | -831.72 | -611.13 | -548.28 | -420.85 | Upgrade
|
| Net Income to Common | -806.74 | -831.72 | -611.13 | -548.28 | -420.85 | Upgrade
|
| Shares Outstanding (Basic) | 63 | 53 | 45 | 44 | 42 | Upgrade
|
| Shares Outstanding (Diluted) | 63 | 53 | 45 | 44 | 42 | Upgrade
|
| Shares Change (YoY) | 19.59% | 16.95% | 1.01% | 5.45% | 5.39% | Upgrade
|
| EPS (Basic) | -12.84 | -15.83 | -13.60 | -12.33 | -9.98 | Upgrade
|
| EPS (Diluted) | -12.84 | -15.83 | -13.60 | -12.33 | -9.98 | Upgrade
|
| Free Cash Flow | -734.04 | -755.94 | -506.06 | -483.57 | -290.57 | Upgrade
|
| Free Cash Flow Per Share | -11.68 | -14.39 | -11.26 | -10.87 | -6.89 | Upgrade
|
| Gross Margin | 51.23% | 52.91% | 75.10% | 54.47% | 83.65% | Upgrade
|
| Operating Margin | -372.05% | -588.02% | -372.83% | -1592.72% | -6970.76% | Upgrade
|
| Profit Margin | -470.91% | -620.25% | -395.49% | -1618.40% | -6901.49% | Upgrade
|
| Free Cash Flow Margin | -428.47% | -563.74% | -327.50% | -1427.38% | -4764.97% | Upgrade
|
| EBITDA | -634.55 | -785.67 | -573.71 | -538.06 | -422.29 | Upgrade
|
| D&A For EBITDA | 2.83 | 2.83 | 2.41 | 1.52 | 2.79 | Upgrade
|
| EBIT | -637.37 | -788.5 | -576.12 | -539.58 | -425.08 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.